Vertex (NASDAQ: VRTX) shareholder files to sell 1,500 shares
Filing Impact
Filing Sentiment
Form Type
144
Rhea-AI Filing Summary
Vertex Pharmaceuticals shareholder Ourania Tatsis filed a Form 144 notice to sell 1,500 shares of Vertex common stock, with an aggregate market value of $749,992.02, through Fidelity Brokerage Services on NASDAQ around February 13, 2026.
The filing indicates 253,718,831 Vertex common shares outstanding. The 1,500 shares to be sold trace to restricted stock that vested as compensation in February 2021, in lots of 1,448 and 52 shares acquired from the issuer.
Over the past three months, Tatsis has sold additional Vertex common shares, including 4,500 shares on December 3, 2025 for gross proceeds of $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38.
Positive
- None.
Negative
- None.
FAQ
What does the Form 144 filing for Vertex (VRTX) by Ourania Tatsis disclose?
The Form 144 discloses that shareholder Ourania Tatsis plans to sell 1,500 shares of Vertex common stock. The shares have an aggregate market value of $749,992.02 and are expected to be sold on the NASDAQ through Fidelity Brokerage Services.
What prior Vertex (VRTX) stock sales has Ourania Tatsis reported in the last three months?
The filing shows three prior sales: 4,500 shares on December 3, 2025 for $2,024,955.40, 4,500 shares on January 7, 2026 for $2,137,455.00, and 466 shares on February 11, 2026 for $214,560.38 in gross proceeds.